AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Univercells","sponsor":"ReiThera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Univercells","sponsor":"Exyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Univercells","sponsor":"Codagenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Univercells","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Univercells

    Menu

    Univercells

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Univercells

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

              Details:

              Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform to prevent, treat, and cure diseases in a range of fields from oncology to infectious diseases.

              Lead Product(s): mRNA-based Vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: Altamira Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Univercells

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine

              Details:

              Partnership will utilize scale-X™ for Codagenix's pipeline including vaccine candidates for SARS-CoV-2 COVI-VAC™, respiratory syncytial virus (CodaVax™-RSV); influenza (CodaVax™-H1N1); dengue virus; and triple negative breast cancer (using a rationally designed virus).

              Lead Product(s): COVI-VAC

              Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC

              Highest Development Status: Phase I Product Type: Vaccine

              Recipient: Codagenix

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Univercells

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine

              Details:

              Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.

              Lead Product(s): COVID-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Recipient: Exyte

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Univercells

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine

              Details:

              The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

              Lead Product(s): Adenoviral vector-based vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Recipient: ReiThera

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY